BeStock  
Stocks › Biotechnology › DNLI

Denali Therapeutics DNLI

US equityMarket cap rank #2440Biotechnology
$18.45 +$0.25 (+1.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $18.45 0.00%
Open$17.97
Prev close$18.20
Day range$17.92 – $18.85
Volume2.63M
Market cap$2.96B
P/E (TTM)–
Dividend yield–
Founded2013
CEODr. Ryan J. Watts, PhD
Employees503
HeadquartersSan Francisco, United States of America
Websitewww.denalitherapeutics.com

Revenue per employee

$18.1K$424.6K$831.1K$1.2MDec '18Dec '20Dec '23

503 employees as of 2025/FY (+19.2% YoY). Revenue per employee is total revenue divided by headcount — a rough productivity gauge, not a per-worker pay figure.

Management team

Dr. Ryan J. Watts, PhD Director, President and Chief Executive Officer
Age 50 · Total comp. $4,751,515.00 · As of 20 Apr 2026
Background

Ryan J. Watts, Ph.D. is one of our co-founders and has served as a member of our board of directors since March 2015 and as our President and Chief Executive Officer since August 2015. Previously, Dr. Watts was at Genentech, a biotechnology company, where he held various research and leadership roles of increasing responsibility between 2004 and 2015; including his time served as Director of the Department of Neuroscience from 2013 to February 2015. In addition, Dr. Watts led Genentech's blood-brain barrier team between 2009 and 2015. Dr. Watts has authored and co-authored more than 60 scientific papers and has been an inventor on a number of patents in the blood-brain barrier and neurodegeneration fields. Dr. Watts currently serves on the board of privately held healthcare company Peel Therapeutics. Dr. Watts is an Adjunct Professor in the Chemical and System Biology Department at Stanford University and an Adjunct Professor in the School of Biological Sciences at University of Utah. Dr. Watts received his Ph.D. in biological sciences from Stanford University and his B.S. in biology from the University of Utah.

Dr. Alexander O. Schuth, M.D. Secretary, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer
Age 51 · Total comp. $4,258,045.00 · As of 20 Apr 2026
Background

Alexander O. Schuth, M.D. is one of our co-founders and has served as our Chief Operating Officer since March 2015 and as Secretary since June 2015. On March 14, 2022, the Board appointed Dr. Schuth to the role of Chief Financial Officer, effective as of May 1, 2022. As of this date, Dr. Schuth became the Company's Chief Operating and Financial Officer, and retained his role as Secretary of the Company. Dr. Schuth co-founded and joined Denali from Genentech, where he held various roles of increasing responsibility between 2005 and 2015; from September 2014 to March 2015, Dr. Schuth served as Head of Technology Innovation and Diagnostics Partnering; from March 2010 to September 2014, Dr. Schuth served as Head of Neuroscience Partnering; from January 2007 to March 2010, Dr. Schuth worked in the business development team; and from August 2005 to January 2007, Dr. Schuth worked as an R&D finance manager. From January 2001 to May 2003, he served as Investment Banking Associate in the equity capital markets group at Merrill Lynch in London. He currently serves on the board of directors of Molecular Health GmbH, a privately held biopharmaceutical company. Dr. Schuth received his M.B.A. from The Wharton School of the University of Pennsylvania and his M.D. from the Charite Medical School at the Humboldt University in Berlin, Germany.

Julian C. Baker Chairman of the Board
Age 59 · Total comp. $474,348.00 · As of 20 Apr 2026
Background

Julian C. Baker is a Managing Member of Baker Bros. Advisors LP (BBA), a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations. Mr. Baker founded BBA, together with his brother Felix Baker, in 2000. Prior to BBA, Mr. Baker was a portfolio manager at Tisch Financial Management from 1994 to 1999. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. Mr. Baker currently serves on the boards of directors of public companies Acadia Pharmaceuticals, Inc., Incyte Corporation, Madrigal Pharmaceuticals, Inc., and Prelude Therapeutics, Inc. Mr. Baker holds an A.B. from Harvard University.

Tim Van Hauwermeiren, M. Sc. Independent Director
Age 54 · Total comp. $467,961.00 · As of 20 Apr 2026
Background

Tim Van Hauwermeiren has served on our board of directors since November 2025. He co-founded argenx SE and has served as its Chief Executive Officer since 2008. Since 2017, he has also served as a director of the company. In addition he has served as an independent director on the boards of public companies, including iTeos Therapeutics, RayzeBio, and Lexeo Therapeutics, as well as private company Aelin Therapeutics. Mr. Van Hauwermeiren has broad training and experience in biotech and innovation management. He holds a degree in BioEngineering from the University of Ghent and an executive M.B.A. from Vlerick Business School.

Peter S. Klein Independent Director
Age 63 · Total comp. $318,880.00 · As of 20 Apr 2026
Background

Peter Klein has served as a member of our board of directors since March 2018. Mr. Klein served as Chief Financial Officer of William Morris Endeavor Entertainment, LLC (WME), a marketing firm, from January 2014 to June 2014. Prior to joining WME, Mr. Klein served as Chief Financial Officer at Microsoft Corporation from November 2009 until May 2013. Mr. Klein previously served on the boards of directors of F5 Inc., Apptio, Inc., Sarcos Technology and Robotics Corporation, and Accolade, Inc. Mr. Klein holds a B.A. in history from Yale University and an M.B.A. from the University of Washington.

Jay T. Flatley Independent Director
Age 73 · Total comp. $316,380.00 · As of 20 Apr 2026
Background

Jay Flatley has served as a member of our board of directors since April 2015. Mr. Flatley is currently President and CEO of Radian Bio. Mr. Flatley served as the Chairman and Acting Chief Executive Officer of Zymergen Inc. until it was acquired by Gingko Bioworks in 2022. Mr. Flatley previously spent over 20 years serving in various leadership roles at Illumina, Inc., a public company focused on sequencing- and array-based solutions for genetic analysis. His roles included Chairman of the board of directors from January 2020 to May 2021, Executive Chairman from July 2016 to January 2020, Chief Executive Officer from December 2013 to July 2016, and Chief Executive Officer and President from October 1999 to December 2013. Prior to joining Illumina, Mr. Flatley was co-founder, President, Chief Executive Officer, and a director of Molecular Dynamics, a life sciences company focused on genetic discovery and analysis, from July 1994 until its sale to Amersham Pharmacia Biotech in September 1998. Mr. Flatley also serves as Chairman of the Wellcome Trust Leap Fund, is Chairman of the board of Cellanome, is on the board of directors at Rivian Automotive, on the board of trustees for The Salk Institute, and is an Advisory Board member for UC San Diego's Moores Cancer Center. Mr. Flatley previously served on the boards of directors of Iridia, Zymergen, Juno Therapeutics, and Coherent Inc. Mr. Flatley received his B.S. and M.S. in industrial engineering from Stanford University and his B.A. in economics from Claremont McKenna College.

Dr. David P. Schenkein, M.D. Independent Director
Age 68 · Total comp. $311,380.00 · As of 20 Apr 2026
Background

David Schenkein, M.D. has served as a member of our board of directors since April 2015. Dr. Schenkein currently is a general partner in GV (Google Ventures). Previously, Dr. Schenkein served as President and Chief Executive Officer of Agios Pharmaceuticals from August 2009 to January 2019. From March 2006 to July 2009, Dr. Schenkein served as a Senior Vice President of Oncology Development at Genentech. Dr. Schenkein currently serves on the boards of directors of Regeneron Pharmaceuticals and Prime Medicine, each of which is a public company, and on the boards of directors of a number of private companies. Previously, Dr. Schenkein served on the boards of directors of Agios Pharmaceuticals, Bluebird Bio, and Foundation Medicine. He also currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Dr. Schenkein received his M.D. from the State University of New York Upstate Medical School and his B.A. in chemistry from Wesleyan University.

Nancy A. Thornberry Independent Director
Age 69 · Total comp. $306,380.00 · As of 20 Apr 2026
Background

Nancy A. Thornberry has served on our board of directors since January 2021. Ms. Thornberry served as Chief Executive Officer of Kallyope, Inc. from November 2015 until October 2021, and currently serves on its board of directors and as Chair, R&D. Ms. Thornberry also serves on the boards of directors of Vertex Pharmaceuticals and Schrodinger, both of which are public companies, Adimab, a private company, and NY Genome Center, a non-profit institution; she previously served on the boards of Intarcia Therapeutics and Abide Therapeutics. Between August 2013 and October 2015, Ms. Thornberry was self-employed as a consultant to companies in the biotechnology and pharmaceutical industries. Prior to that, Ms. Thornberry spent over 30 years at Merck, a pharmaceutical company, where she held a variety of positions including Senior Vice President and Franchise Head, Diabetes and Endocrinology, from April 2011 to July 2013, Senior Vice President and Franchise Head, Diabetes and Obesity, from September 2009 to April 2011, Vice President, Worldwide Basic Research Head, Diabetes and Obesity, from February 2007 to September 2009, and Executive Director, Metabolic Disorders, from 2004 to February 2007, among other positions. Ms. Thornberry received a B.S. in Chemistry and Biology from Muhlenberg College.

Jennifer E. Cook Independent Director
Age 60 · Total comp. $301,380.00 · As of 20 Apr 2026
Background

Jennifer Cook has served on our board of directors since November 2018. Ms. Cook currently is the owner of Jennifer Cook Consulting and serves as an advisor at Google Ventures. Ms. Cook served as the Chief Executive Officer of GRAIL from January 2018 to June 2019. Previously, Ms. Cook was at Roche Pharmaceuticals and Genentech, where she held a number of senior management positions; from January 2017 to December 2017, Ms. Cook served as Senior Vice President, Global Head of Clinical Operations for Roche Pharmaceuticals; from September 2013 to December 2016, Ms. Cook served as Head of Region Europe Pharma for Roche Pharmaceuticals; and from July 2010 to September 2013, Ms. Cook served as the Senior Vice President, Business Unit Head Immunology and Ophthalmology for Genentech. Ms. Cook currently also serves on the boards of directors of BridgeBio Pharma, Inc. and Jazz Pharmaceuticals. Ms. Cook holds a B.A. in human biology and an M.S. in biology from Stanford University, as well as an M.B.A. from the Haas School of Business at University of California, Berkeley.

Steven E. Krognes, M.B.A. Director
Age 57 · Total comp. $297,149.00 · As of 20 Apr 2026
Background

Steve E. Krognes served as Chief Financial Officer and Treasurer of Denali Therapeutics from October 2015 until April 30, 2022; on May 1, 2022 he was appointed to the board of directors. Mr. Krognes joined Denali from Genentech, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech's Site Services organization between 2011 and 2015, and Genentech's IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation between 2009 and 2015. From January 2004 to April 2009, Mr. Krognes served as Head of Mergers & Acquisitions and a member of the Finance Executive Committee at Roche, a Swiss biotechnology company. From July 2002 to December 2003, Mr. Krognes served as Director of M&A at Danske Bank based in Norway. Mr. Krognes currently serves on the boards of directors of public companies Pliant Therapeutics, Guardant Health, and argenx SE, private company ClavystBio, and previously served on the boards of Corvus Pharmaceuticals, Inc., Gritstone bio, Inc., and RLS Global AB. Mr. Krognes also served as a board member of the California Life Science Association from 2010 to 2015 and California Academy of Sciences from 2014 to 2018. He received his M.B.A. from Harvard Business School and his B.S. in Economics from The Wharton School of the University of Pennsylvania.

Peter Scott Chin Chief Medical Officer and Head of Development
Age 58 · As of 20 Apr 2026
Background

Peter Chin, M.D. has served as our Chief Medical Officer, Head of Development since March 2026, when he transitioned from Acting Chief Medical Officer, which he assumed following Dr. Ho's departure in November 2025. Dr. Chin joined Denali in 2019 as Senior Vice President of Late-Stage Clinical Development and established the medical affairs, drug safety, and health economics and outcomes research functions. Before joining Denali, Dr. Chin spent nearly 15 years in clinical development and medical affairs at Genentech, Roche and Novartis. Dr. Chin completed his residency in Neurology at the University of Washington. He received his M.D. from Dartmouth and B.A. in Molecular and Cell Biology from the University of California, Berkeley. Dr. Chin trained as a Robert Wood Johnson Foundation Clinical Scholar at the University of California, Los Angeles, where he also received an M.S. in Health Services Research from the School of Public Health.

From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.

Sectors & themes

Discussion

No comments yet — be the first to weigh in on DNLI.

Sign in to join the discussion.

Scroll to Top